Recently, Hengrui Pharmaceuticals' subsidiary Fujian Shengdi Pharmaceutical Co., Ltd. received the Approval Notice of Drug Clinical Trial issued by the State Drug Administration, which approved the company's HRS5580 for injection to carry out clinical trials for the prevention of postoperative nausea and vomiting.

Postoperative nausea and vomiting (PONV) mainly occurs within 24 hours after surgery, but can also be as long as 3~5 days, is one of the common complications of surgery. The incidence of PONV is estimated to be 20% to 37%, with a probability of up to 80% in high-risk patients. Nausea and vomiting can be a distressing experience for patients when combined with postoperative pain. The effectiveness of the current main clinical agents for the prevention of PONV for the prevention of vomiting after surgery needs to be improved, and the development of new therapeutic agents is urgently needed.

HRS5580 for injection is an injectable agent independently developed by Hengrui Pharmaceuticals' subsidiary, Fujian Shengdi Pharmaceutical Co., Ltd. and exerts antiemetic effects by antagonizing NK-1 receptors. With a long half-life and a high degree of central nervous system permeability, it is expected to further improve the effectiveness of preventing postoperative vomiting and has certain advantages for people with a long duration of postoperative vomiting.

Based on the above characteristics, HRS5580 for injection is expected to help clinically improve the adherence of PONV patients and increase the clinical benefits from standardized drug use. Currently, there is no similar drug of HRS5580 for injection on the market in China.

https://mp.weixin.qq.com/s?__biz=MzU4Njc2Njc0NA==&mid=2247520402&idx=1&sn=5dacd41edc84ab8eeb03d7c0f5f3c2e7&chksm=fdf49065ca831973c6287e44aa021daee72c97b2a4f2e133a1e19232b5b89e2c2bf3df7dd12f&mpshare=1&scene=1&srcid=05108kTDvIDm09QZApthNRPQ&sharer_shareinfo=22bef0a51680406b173519786e144be1&sharer_shareinfo_first=22bef0a51680406b173519786e144be1#rd